Trial · NCT05369832
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 32
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Colitis ulcerative | Gastrointestinal disorders | Cohort 1: Ozanimod Advanced Therapy Naive | 13 | 99 | |
| other | Colitis ulcerative | Gastrointestinal disorders | Cohort 2: Ozanimod Advanced Therapy Exposed | 4 | 40 | |
| other | Nasopharyngitis | Infections and infestations | Cohort 1: Ozanimod Advanced Therapy Naive | 5 | 99 | |
| other | Nasopharyngitis | Infections and infestations | Cohort 2: Ozanimod Advanced Therapy Exposed | 1 | 40 | |
| other | Sinusitis | Infections and infestations | Cohort 1: Ozanimod Advanced Therapy Naive | 0 | 99 | |
| other | Sinusitis | Infections and infestations | Cohort 2: Ozanimod Advanced Therapy Exposed | 4 | 40 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort 1: Ozanimod Advanced Therapy Naive | 7 | 99 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort 2: Ozanimod Advanced Therapy Exposed | 1 | 40 | |
| other | Headache | Nervous system disorders | Cohort 1: Ozanimod Advanced Therapy Naive | 5 | 99 | |
| other | Headache | Nervous system disorders | Cohort 2: Ozanimod Advanced Therapy Exposed | 0 | 40 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 1: Ozanimod Advanced Therapy Naive | 1 | 99 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 2: Ozanimod Advanced Therapy Exposed | 0 | 40 | |
| serious | Colitis ulcerative | Gastrointestinal disorders | Cohort 1: Ozanimod Advanced Therapy Naive | 2 | 99 | |
| serious | Colitis ulcerative | Gastrointestinal disorders | Cohort 2: Ozanimod Advanced Therapy Exposed | 1 | 40 | |
| serious | Pancreatitis | Gastrointestinal disorders | Cohort 1: Ozanimod Advanced Therapy Naive | 1 | 99 | |
| serious | Pancreatitis | Gastrointestinal disorders | Cohort 2: Ozanimod Advanced Therapy Exposed | 0 | 40 | |
| serious | Appendicitis | Infections and infestations | Cohort 1: Ozanimod Advanced Therapy Naive | 2 | 99 | |
| serious | Appendicitis | Infections and infestations | Cohort 2: Ozanimod Advanced Therapy Exposed | 0 | 40 | |
| serious | Comminuted fracture | Injury, poisoning and procedural complications | Cohort 1: Ozanimod Advanced Therapy Naive | 1 | 99 | |
| serious | Comminuted fracture | Injury, poisoning and procedural complications | Cohort 2: Ozanimod Advanced Therapy Exposed | 0 | 40 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05369832/events